Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas

Clinical trial NCT02419287 · COMPLETED

Trial details

NCT number: NCT02419287
Sponsor: University of Milano Bicocca
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Anaplastic Large Cell Lymphoma, ALK-Positive

Start date: 2015-04-01
Primary completion: 2022-12-01
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.